Heron Therapeutics Inc. (NASDAQ:HRTX) Given Consensus Recommendation of “Buy” by Analysts
Shares of Heron Therapeutics Inc. (NASDAQ:HRTX) have been assigned an average recommendation of “Buy” from the nine research firms that are covering the stock. One research analyst has rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $41.50.
Several research analysts have commented on HRTX shares. Zacks Investment Research lowered shares of Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, August 3rd. Leerink Swann restated a “buy” rating and issued a $33.00 price objective on shares of Heron Therapeutics in a report on Sunday, October 2nd. Cantor Fitzgerald restated a “buy” rating and issued a $41.00 price objective on shares of Heron Therapeutics in a report on Wednesday, August 3rd. Lake Street Capital restated a “buy” rating and issued a $45.00 price objective on shares of Heron Therapeutics in a report on Tuesday, September 6th. Finally, Jefferies Group decreased their price target on shares of Heron Therapeutics from $46.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, October 3rd.
Heron Therapeutics (NASDAQ:HRTX) traded up 1.78% on Monday, reaching $17.13. 284,884 shares of the company traded hands. The stock’s 50 day moving average price is $18.62 and its 200 day moving average price is $18.90. Heron Therapeutics has a one year low of $15.13 and a one year high of $31.32.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/10/heron-therapeutics-inc-nasdaqhrtx-given-consensus-recommendation-of-buy-by-analysts.html
Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.17) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.96) by $0.21. Analysts predict that Heron Therapeutics will post ($4.39) EPS for the current fiscal year.
In other Heron Therapeutics news, insider Robert Rosen sold 100,000 shares of the firm’s stock in a transaction dated Wednesday, August 10th. The shares were sold at an average price of $23.30, for a total transaction of $2,330,000.00. Following the completion of the sale, the insider now directly owns 102,640 shares in the company, valued at approximately $2,391,512. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 20.31% of the company’s stock.
Hedge funds have recently added to or reduced their stakes in the stock. Cormorant Asset Management LLC raised its stake in Heron Therapeutics by 3.8% in the first quarter. Cormorant Asset Management LLC now owns 1,750,000 shares of the biotechnology company’s stock worth $33,233,000 after buying an additional 64,281 shares in the last quarter. JPMorgan Chase & Co. raised its stake in Heron Therapeutics by 6.0% in the first quarter. JPMorgan Chase & Co. now owns 348,685 shares of the biotechnology company’s stock worth $6,622,000 after buying an additional 19,737 shares in the last quarter. VHCP Management II LLC purchased a new stake in Heron Therapeutics during the first quarter worth $7,708,000. California State Teachers Retirement System raised its stake in Heron Therapeutics by 7.6% in the second quarter. California State Teachers Retirement System now owns 66,632 shares of the biotechnology company’s stock worth $1,203,000 after buying an additional 4,732 shares in the last quarter. Finally, Brown Advisory Inc. raised its stake in Heron Therapeutics by 3.9% in the second quarter. Brown Advisory Inc. now owns 307,827 shares of the biotechnology company’s stock worth $5,557,000 after buying an additional 11,471 shares in the last quarter.
About Heron Therapeutics
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.